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Despite the advances in anticancer drug discovery field, theworldwide cancer incidence is remarkable, highlighting the need for new
therapies focusing on both cancer cell and its microenvironment. The tumor microenvironment offers multiple targets for cancer
therapy, including inflammation. Nowadays, almost 75% of the anticancer agents used in chemotherapy are derived from natural
products, and plants are an important source of new promising therapies. Continuing our research on Piper umbellatum species,
here we describe the anticancer (in vitro antiproliferative activity and in vivo Ehrlich solid tumor model) and anti-inflammatory
(carrageenan-induced paw edema and peritonitis models) activities of a standardized dichloromethane extract (SDE) from P.
umbellatum leaves, containing 23.9% of 4-nerolidylcatechol. SDE showed in vitro and in vivo antiproliferative activity, reducing
Ehrlich solid tumor growth by 38.7 and 52.2%when doses of 200 and 400mg/kg, respectively, were administered daily by oral route.
Daily treatments did not produce signals of toxicity. SDE also reduced paw edema and leukocytemigration on carrageenan-induced
inflammation models, suggesting that the anticancer activity of SDE from Piper umbellatum leaves could involve antiproliferative
and anti-inflammatory effects. These findings highlight P. umbellatum as a source of compounds against cancer and inflammation.
1. Introduction
Nature has been a source ofmedicinal products formillennia,
going along with the history of humanity. Due to the
improvement on methods for isolation, identification, and
synthesis during the last century, many drugs have arisen
from natural sources. In chemotherapy field, around 75% of
the anticancer agents used nowadays are derived fromnatural
products of different origins, including plants, microorgan-
isms, and marine organisms [1]. One important example of
natural source is the Piper genus (Piperaceae family), which
comprises approximately 2000 species, distributed mainly
in tropical areas and widely evaluated for their medici-
nal properties [2]. Piper umbellatum L. (syn. Pothomorphe
umbellata (L.) Miq., Lepianthes umbellata (L.) Raf., Heckeria
umbellata (L.) Kunth, and Peperomia umbellata (L.) Kunth)
is a perennial shrub or woody herb, popularly known in
Brazil as pariparoba, caapeba, and malvarisco [3]. Other
synonyms for Piper umbellatum L. have been suggested,
although some of them are still under revision (available on
http://www.theplantlist.org/tpl1.1/record/kew-2571246).
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This species was included in the Brazilian Pharmacopoeia
first edition (1926) and 94 traditional medicinal uses for
P. umbellatum are registered [3]. Indeed, there are several
pharmacological activities described, such as antioxidant
[4], anti-inflammatory and analgesic [5], antibacterial [6],
antifungal [7], antitumor [8] activities and protection against
photoaging [9] and anticonvulsants [10]. Moreover, phy-
tochemical studies of P. umbellatum leaves extracts have
demonstrated the presence of terpenes, alkaloids, flavonoids,
and sterols, the catechol 4-nerolidylcatechol (4-NC) being the
majority compound [3, 6, 11].
Previous studies performed by our group evaluated the in
vitro and in vivo anticancer activities of a dichloromethane
crude extract (DCE) from P. umbellatum leaves and its
fractions, showing that intraperitoneal (i.p.) treatment with
DCE (200mg/kg) increased the life span of Ehrlich ascitic
tumor-bearing animals and that treatment with a higher dose
(400mg/kg) promoted toxicity [8]. Another study conducted
by our group demonstrated that Piper regnellii DCE and its
fractions inhibited Ehrlich solid tumor development in mice
[12].
The emergence of a cancer (carcinogenesis) is a complex
and multistep process during which normal cells progres-
sively acquire a neoplastic phenotype. Each genetic modifi-
cation confers to tumor cells a type of advantage, constituting
the hallmarks of cancer, such as self-sustained proliferation,
evasion of growth signals suppressors, resistance to cell death,
limitless replication, inducing angiogenesis, and activating
invasion and metastasis processes [13]. Besides cancer hall-
marks, the tumor microenvironment also influences cancer
development, and one prominent microenvironment stimu-
lus in carcinogenesis is inflammation [14].
Despite the advances in the field of anticancer drug
discovery, the statistics are noteworthy; in 2012, 14.1 million
new cases of cancer were diagnosed worldwide, with 8.2
million deaths [15].Thus, there is still a necessity for the devel-
opment of new therapies and the tumor microenvironment
is an important source of multiple targets for cancer therapy,
including inflammation [16].
Bearing in mind the need for new therapies, specially
focusing on the tumor microenvironment and the potential
of Piper umbellatum as an anticancer agent, in this study we
evaluated the in vitro and in vivo antiproliferative activities of
a standardized dichloromethane crude extract (SDE) from P.
umbellatum leaves, containing 23.9% of 4-NC. We also eval-
uated its anti-inflammatory activity, looking for evidences
of the relationship between the SDE anticancer and anti-
inflammatory activities.
2. Materials and Methods
2.1. Plant Material. Piper umbellatum leaves were collected
in February 2013 at an experimental field of the Chemical,
Biological and Agricultural Pluridisciplinary Research Cen-
ter (CPQBA, UNICAMP, Paul´ınia, SP, Brazil). A voucher
specimen was deposited at the Herbarium of Institute of
Biology, University of Campinas (UEC number 181.451). As
P. umbellatum is a Brazilian native genetic material, the
present study had been approved by the Genetic Patrimony
Management Board (CGEN/MMA), through Access and
Shipment Component of Genetic Heritage for scientific
research purpose (number 010646/2012-4).
2.2. Dichloromethane Crude Extract Production. Milled
fresh leaves (1 kg) were extracted by maceration with
dichloromethane (Dinamica) (1 : 5 leaves : solvent, 3 ×
90min) at room temperature. After filtration, the filtrates
were pooled, evaporated (40∘C, BUCHI model RE 215), and
lyophilized (Virtis, model 8L) until dryness, affording DCE
(2% yield).
2.3. Isolation of 4-Nerolidylcatechol. DCE was previously
cleaned up for pigments and other lipophilic compounds (1 g)
through liquid partition with hexane : acetonitrile (1 : 1) (3 ×
100mL). The acetonitrile phase (680mg) was then applied
on a solid-phase extraction (SPE) cartridge C18-E (55𝜇M,
70A, and 5 g/20mL) Phenomenex previously conditioned
with 10mLmethanol and 10mL water, at 5mL/min flow rate.
SPE cartridge was eluted with 2 × 10mL water :methanol
(95 : 5, 50 : 50, 85 : 15, and 0 : 100, named as FA, FB, FC, and
FD, resp.), at 3.5mL/min flow rate. Fraction FC (190mg) was
analysed by RMN1H and 13C.
2.4. Chromatographic Analysis. HPLC analysis followed a
previously described protocol [17]. It was performed with a
Shimadzu seriesHPLC system equippedwith online degasser
(DUG-2A), quaternary pump (LC-10AT), autosampler (SIL
20A HT), column heater (CTO 10AS Vp), and photodiode
array detector (SPD-M10Vp), using a C18 column (4.6mm ×
250mm, 5𝜇m particle size, Gemini, Phenomenex, Maccles-
field, UK). Instrument control and data analysis was carried
out using software ClassVP 6.13 edition.The isocratic mobile
phase wasmethanol-acetonitrile-water (62 : 20 : 18). Flowwas
set at 1.0mL/min, injection volumewas 20 𝜇L, and ultraviolet
detection was at 282 nm.
2.5. Quantification of 4-Nerolidylcatechol. 4-NC was quan-
tified in the DCE by analytical curve. Stock solutions
(2396 𝜇g/mL) were prepared in methanol and successively
diluted in the range of 48 to 957𝜇g/mL, two replicates each, in
methanol. All samples were analyzed by HPLC as described
in Chromatographic Analysis. A graphic correlating area
under the curve (AUC) with the respective concentration
was plotted and analyzed by linear regression usingMS Excel
software (Supplementary Figures S1 and S2 in Supplementary
Material available online at http://dx.doi.org/10.1155/2015/
948737). After quantification, DCE was defined as standard-
ized dichloromethane extract (SDE).
2.6. In Vitro Antiproliferative Assay
2.6.1. Cell Lines. Human tumor cell lines (UACC-62 (mela-
noma), U251 (glioma), MCF-7 (breast), NCI-H460 (lung,
non-small cells), HT-29 (colon), PC-3 (prostate), 786-0
(kidney), NCI-ADR/RES (ovarian expressing multiple drugs
resistance phenotype), and OVCAR-3 (ovary)) were kindly
provided by the National Cancer Institute (Frederick, MA,
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USA). Nontumor cell line HaCat (human keratinocytes)
was donated by Professor Dr. Ricardo Della Coletta, FOP/
UNICAMP.
2.6.2. Cell Culture. Stock cultures were grown in medium
RPMI 1640 (GIBCO) supplemented with 5% fetal bovine
serum (FBS, GIBCO) and 10U/mL penicillin, 10 𝜇g/mL
streptomycin at 37∘C in 5% CO
2
.
2.6.3. Antiproliferative Assay. Cells in 96-well plates (100 𝜇L
cells/well) were exposed to SDE (0.25, 2.5, 25, and 250𝜇g/mL
in DMSO/RPMI) at 37∘C, 5% of CO
2
in air for 48 h. Dox-
orubicin (DOXO) was used as standard (0.025, 0.25, 2.5, and
25 𝜇g/mL). Final DMSO concentration did not affect cell via-
bility (0.25%). Before (T0 plate) and after (T1 plates) sample
addition, cells were fixed with 50% trichloroacetic acid and
cell growth was determined by spectrophotometric quantifi-
cation (540 nm) of cellular protein content using sulforho-
damine B (SRB) assay [18]. The TGI (concentration that pro-
duces total growth inhibition) was determined through non-
linear regression analysis using the concentration-response
curve for each cell line in the software ORIGIN 8.0 (Origin-
Lab Corporation) [19].
2.7. In Vivo Assays
2.7.1. Animals. Experiments were conducted with Balb/C
and Swiss female mice (20–30 g, 90 days old) from the
Multidisciplinary Centre for Biological Investigation on Lab-
oratory Animals Sciences (CEMIB, UNICAMP). Animals
were maintained at the Animal Facilities of Pharmacology
and Toxicology Division, CPQBA, UNICAMP (Paul´ınia, SP,
Brazil), in a room with controlled temperature 25 ± 2∘C
for 12 h light/dark cycle, with free access to food and water.
Animal care and research protocols were in accordance
with the principles and guidelines adopted by the Brazilian
College of Animal Experimentation (COBEA). Protocols
were approved by the Ethical Committee forAnimal Research
(CEUA), Institute of Biology, UNICAMP (numbers 2868-
1, 3182-1, 3052-1, and 3183-1). Euthanasia was performed by
deeping anaesthesia followed by cervical dislocation.
2.7.2. Drugs. The used drugs were Indocid (indomethacin
50mg;Merck Sharp&Dohme), carrageenan (Sigma-Aldrich,
EUA), and dexamethasone (Sigma-Aldrich, EUA). SDE was
emulsified in Tween 80 (Sigma) 0.3% and dissolved in PBS,
pH 7.0. Vehicle was PBS, pH 7.0 + Tween 80 (Sigma) 0.3%.
2.7.3. Acute Toxicity. Swiss mice (𝑛 = 5) were fasted for 12 h
and then treated orally with SDE 1000 and 2000mg/kg.
Groups were observed during 4 hours and then daily for
15 days, for general toxicity signals evaluation: body weight
loss, locomotion, behaviour (agitation, lethargy), respiration,
salivation, tearing eyes, cyanosis, and mortality [20].
2.7.4. Subchronic Toxicity. Balb/C mice (𝑛 = 6) were treated
orally with vehicle and SDE (100, 200, and 400mg/kg), daily,
for 21 days. Mice were weighed (every three days) and daily
observed for possible signals of toxicity [20]. At the 21st
day, whole blood was collected from the retroorbital plexus
of each animal for complete blood count analyses (Sysmex
model Poch-100iV) evaluating total leukocytes (WBC), ery-
throcytes (RBC), and platelets (Pt) count. Animals were euth-
anized and liver, spleen, and kidneys were macroscopically
evaluated and weighed.
2.7.5. Ehrlich Solid Tumor Assay
Cells Maintenance and Preparation. Ehrlich tumor cells were
maintained in the ascitic form in Swiss mice by weekly
transplantation of 5 × 105 cells/animal in PBS (pH 7.0) [21].
For the experiments, cells were prepared at the density of 1 ×
106 cells/50 𝜇L/animal in PBS [22] after count in Neubauer
chamber with trypan blue, to exclude nonviable cells and
debris.
Induction and Treatments. Ehrlich cells suspension (1 ×
106 cells/50 𝜇L/animal) was inoculated subcutaneously in the
flank of Balb/C mice (𝑛 = 8). On the 5th day, animals with
palpable tumors were randomly divided into negative control
(vehicle) and experimental (SDE: 100, 200, and 400mg/kg)
groups that were treated every day, orally, for 12 days. On the
17th day, animals were euthanized and tumors were removed
and weighted. The relative tumor weight was calculated
as tumor weight divided by corporal weight. The growth
inhibition ratio was calculated according to the formula [(𝐴−
𝐵)/𝐴] × 100, where 𝐴 is mean relative tumor weight of
negative control group and𝐵 is mean of relative tumorweight
from treated group [22].
2.7.6. Carrageenan-Induced Paw Edema. Experiments were
designed according to Posadas et al. [23] with modifications.
Right hind paw basal volume of Balb/C mice (𝑛 = 8)
was measured using a caliper (Mitutoyo) according to the
ellipse oblate formula: 𝑉 = (4/3)𝜋𝑎2𝑏, where 𝑎 is the
paw laterolateral width and 𝑏 is the dorsal-ventral width.
Then animals were randomly divided into negative control
(vehicle), positive control (indomethacin, 10mg/kg), and
experimental (SDE; 100, 200, and 400mg/kg) groups, being
orally treated one hour before inflammation induction by
carrageenan solution inoculation (2.5mg/mL, 40 𝜇L/animal)
into the right hind footpad. The right footpad volume was
evaluated 1.5, 3.0, 4.5, 6.0, 24, 48, and 72 h after carrageenan
inoculation. Results were expressed as paw edema variations
(mL, difference between measured and basal paw volumes)
versus time.
2.7.7. Carrageenan-Induced Peritonitis. Balb/C mice (𝑛 = 8)
were randomly divided into negative control (vehicle), pos-
itive control (dexamethasone, 2.5mg/kg), and experimental
(SDE, 200mg/kg) groups that were orally treated one hour
before peritonitis induction by carrageenan solution inoc-
ulation (500𝜇g/250 𝜇L/animal) into peritoneal cavity. Four
hours later, mice were euthanized and the peritoneal cavity
was washed with 5mL of PBS containing heparin 5 IU/mL.
Total leukocyte was analysed in peritoneal fluid using a
haematology analyser (Sysmex model Poch-100iV).
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Table 1: Concentration (𝜇g/mL) of Piper umbellatum SDE and dox-
orubicin (DOXO) required for total growth inhibition of cell lines
(TGI valuesa).
Cell lines Total growth inhibition (𝜇g/mL)
DOXO SDE
UACC-62 0.9 6.8
U251 1.6 8.2
MCF-7 0.2 9.3
NCI-ADR/RES 1.9 14.9
786-0 1.1 9.1
NCI-H460 1.9 11.5
PC-3 1.9 8.2
OVCAR-3 1.2 8.3
HT-29 6.2 207.3
HaCat 29.1 144.6
aTGI valueswere determined bynonlinear regression analysis usingORIGIN
8.0 (OriginLab Corporation). Experiments were conducted in triplicate and
results are representative of three different experiments.
2.8. Statistical Analyses. Theresults were presented asmean±
SEM.The statistical significance of difference between groups
was assessed by one-way ANOVA, followed by Newman-
Keuls post hoc test using GraphPad Prism 5.0 software.
Values of 𝑃 ≤ 0.05 were considered significant.
3. Results and Discussion
3.1. Quantification of 4-NC. 4-Nerolidylcatechol (94% of
analytical purity) was identified by experimental data com-
parison with those reported by Baldoqui et al. [11]. In our
study, HPLC-DAD quantitative analysis (correlation coef-
ficient 𝑅2 = 0.9995 ± 0.0005; detection limit (LOD) =
11.6 𝜇g/mL; quantification limit (LOQ) = 35.1 𝜇g/mL) showed
that P. umbellatum SDE presented 23.9% of 4-NC, consid-
ering the initial fresh leaves amount. 4-NC was selected as
a chemical marker for the extract standardization since this
compound is readily isolated and easily quantified both by
HPLC-UV-DAD and by GC/MS. Moreover, due to the well-
known potent antioxidant activity of 4-NC, this substance
may be involved in the possible anti-inflammatory activity of
SDE.
3.2. In Vitro Antiproliferative Assay. SDE showed a potent
antiproliferative activity, as it promoted total growth inhibi-
tion of almost all tumor cell lines (TGI values between 6.8
and 14.9 𝜇g/mL), excepting HT-29 cell line (colon, TGI =
207.3𝜇g/mL) (Table 1). Moreover, TGI value (144.6 𝜇g/mL)
for HaCaT cells (nontumor cell line) was higher than those
observed for most of the tumor cell lines, thus suggesting
selectivity for tumor cells. These promising in vitro antipro-
liferative results were in accordance with our previous work
[8] and prompted the study in in vivomodels.
Considering SDE chemical composition, the observed
antiproliferative effect could be partially attributed to the
presence of 4-NC and sterols 𝛽-sitosterol, stigmasterol, and
campesterol, as these compounds had been identified in
P. umbellatum dichloromethane extracts by Sacoman et al.
and Lopes et al. [4, 8].
𝛽-Sitosterol induces apoptosis and G2/M arrest in MDA-
MB-231 (breast), PC-3 (prostate), and HCT (colon) human
tumor cell lines [24]. A proapoptotic activity of 𝛽-sitosterol
was also reported byMoon et al. [25] in murine fibrosarcoma
cells and human leukaemia. Moreover, 4-NC also induces
changes in the cell cycle profile of SK-Mel-147 (melanoma),
promoting a G1 arrest [26]. It is interesting to notice that
Sacoman et al. [8] observed a higher in vitro antiproliferative
effect for the steroids fraction compared to the 4-NC fraction.
Similarly, Lopes et al. [4] observed that the dichloromethane
extract was more potent than the 4-NC and sterol fractions
in an in vitro antioxidant activity model, hypothesizing a
synergic activity of these compounds.
3.3. In Vivo Assays. In view of confirming the in vitro P.
umbellatum antiproliferative effect, the SDE was evaluated
in vivo in the Ehrlich solid tumor model in mice. Previous
studies with P. umbellatum DCE described its in vivo activity
in the Ehrlich ascitic tumor model after intraperitoneal treat-
ment [8]. This model allows evaluation of life span; however,
it presents a limitation: when treatments are conducted by
intraperitoneal route, samples are applied at the same place of
Ehrlich tumor cells growth.This way, it is difficult to elucidate
parameters related to sample absorption and distribution.
Herein, we described the systemic effects of P. umbellatum
SDE, as treatments were performed by oral route and tumor
cells were implanted subcutaneously in the flank of the
animals.
3.4. Acute and Subchronic Toxicity. Before the in vivo anti-
cancer and anti-inflammatory experiments, an acute toxicity
evaluation was conducted in order to determine the maxi-
mum tolerated dose (MTD) that could be used in the long-
term studies without adverse effects. No evidence of toxicity
was observed up to 4 hours after administration of SDE
1000mg/kg by oral route, as well as during the following
14 days, when the animals were kept under observation.
However, animals treatedwith 2000mg/kg died after 4 hours.
Therefore, MTD was determined as 1000mg/kg for single
treatment and to determine doses for repetitive treatmentswe
considered the higher dose as 40% of MTD, as described by
Mi et al. [27], together with two lower doses.This way, in vivo
experiments were carried out with 100, 200, and 400mg/kg
of SDE, by oral route.
In our previous study, a lethal dose 50% (LD
50
) of
533.71mg/kg was determined for single treatment with P.
umbellatum DCE by intraperitoneal route [8]. Herein, oral
LD
50
of SDE could be considered in the range of 1000 to
2000mg/kg. Such loss of toxicity after changing the treatment
route (intraperitoneal to oral route) may suggest that the
substances responsible for adverse effects in SDE could
show low bioavailability and/or be quickly metabolized when
administrated by oral route.
Moreover, when mice were treated every day, during 21
days, with P. umbellatum SDE 100, 200, and 400mg/kg, no
toxic signals and no haematological alterationswere observed
(Table 2). As most chemotherapeutic agents induce collateral
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Table 2: Cell blood count and organs weight (mean ± SEM) from animals treated (oral route) with vehicle and P. umbellatum SDE (100, 200,
and 400mg/kg) during 21 days.
Organs Vehicle 100 200 400
Liver (g) 0.048 ± 0.001 0.045 ± 0.0010 0.046 ± 0.0029 0.051 ± 0.0009
Kidneys (g) 0.012 ± 0.0001 0.012 ± 0.0002 0.013 ± 0.0002 0.012 ± 0.0003
Spleen (g) 0.004 ± 0.0002 0.005 ± 0.0002 0.005 ± 0.0007 0.004 ± 0.0001
Cell blood count
WBC (106/𝜇L) 4.4 ± 0.3 3.3 ± 0.3 3.7 ± 0.7 4.7 ± 0.6
Haemoglobin (g/dL) 14.2 ± 0.3 14.2 ± 0.2 13.9 ± 0.5 13.9 ± 0.2
Platelet (103/𝜇L) 1169 ± 44.5 1278 ± 28.9 1403 ± 76.3 1388 ± 61.9
Vehicle = PBS + Tween 80 0.3%, pH 7.0.
effects, the observed results for P. umbellatum SDE were
encouraging.
3.5. In Vivo Ehrlich Solid Tumor Assay. Solid tumors are
structures resembling organs in their complexity and het-
erogeneity. Inside these tumors there are differences in pH,
oxygen pressure, and nutrient flux, which often contribute
to tumor resistance to chemotherapy due to irregular drugs
distribution inside the tumor matrix. Therefore, the develop-
ment of experimental models to complement in vitro drug
screening is necessary due to the limitations inherent to
cell cultures to predict the behaviour of solid tumors to
chemotherapy [28, 29].
The in vivo anticancer activity of P. umbellatum SDE was
evaluated in the Ehrlich solid tumor model in mice. Ehrlich
tumor is an aggressive and fast growing murine breast
adenocarcinoma, which is able to develop both in the ascitic
and in the solid form, depending on whether it is inoculated
(intraperitoneally or subcutaneously, resp.) [30]. Ehrlich
tumor cells generate a local inflammatory response charac-
terized by increased vascular permeability, which accounts
for edema formation, cell migration, and recruitment of the
immune response [31].
In the end of experiment, the relative tumor weight for
the negative control group was 0.011 ± 0.0012, which was
decreased in 38.7 and 52.2% (𝑃 < 0.05) after daily treatments
with 200 and 400mg/kg of P. umbellatum SDE, without
signals of toxicity, while treatment with 100mg/kg was not
effective (Figure 1).These results are in accordance with those
previously described by our group [8], with the advantage of
loss of toxicity by changing route and treatment frequency.
As discussed for P. umbellatum SDE in vitro antiproliferative
activity, 4-NC and sterols present in SDE could be partly
responsible for SDE in vivo antitumor activity.
Solid tumors are among the leading death causes in west-
ern countries, with growing incidence every year. Although
the prognosis of these patients has been evolved because
of early diagnosis and new antitumor therapies, there is
still a need for new treatments [32]. Therefore, inhibition of
tumor development by P. umbellatum SDE associated with
low toxicity is an exciting result.
Certain types of cancers induce an inflammatory
microenvironment formation, which contributes to tumor
development [33]. As previously mentioned, Hanahan and
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Figure 1: Relative tumor weight of Ehrlich solid tumor after treat-
ment with vehicle and P. umbellatum SDE. Relative tumor weight
was expressed as tumor weight divided by body weight; groups (𝑛 =
8) were treated daily (during 12 days) by oral route with vehicle (PBS,
pH7.0 +Tween 80 0.3%) and SDE 100, 200, and 400mg/kg;ANOVA,
Newman-Keuls Multiple Comparison Test, ∗𝑃 < 0.05, ∗∗𝑃 < 0.01
significantly different from negative control group (vehicle).
Weinberg [13] included inflammation as a facilitator
process, as it provides bioactive molecules such as
growth, survival and angiogenic factors, and enzymes
that modify the extracellular matrix, among others. In some
cases, inflammation is already evident in early stages of
carcinogenesis, by promoting tumor development since the
action of inflammatory cells can lead to mutagenic agents’
release [34].
In view of the relationship between cancer and inflam-
mation, we evaluated P. umbellatum SDE anti-inflammatory
potential in experimental inflammation models in mice.
3.6. In Vivo Anti-Inflammatory Assays. The administration
of carrageenan 2.5% into the mouse hind footpad induces
a biphasic inflammatory edema [35]. Immediately after car-
rageenan injection, there is a cascade of mediators’ release,
as histamine, serotonin, bradykinin, and phospholipase A
2
(PLA
2
). These mediators promote an increase in vascu-
lar permeability and signal for arachidonate metabolites
(prostaglandins, leukotrienes) and nitric oxide release, until
the 6th hour.The second phase of inflammation starts after 24
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Table 3: Inhibitory effect of P. umbellatum SDE versus time after inflammatory stimulus on carrageenan-induced paw edema.
Treatments (mg/kg) Time (hours) and % of inhibition
1.5 3 4.5 6 24 48 72 96
Vehicle 0.15 ± 0.03 0.25 ± 0.03 0.19 ± 0.03 0.05 ± 0.01 0.04 ± 0.001 0.15 ± 0.01 0.16 ± 0.01 0.10 ± 0.02
Indomethacin 10 0.11 ± 0.03
(28.7%)
0.10 ± 0.01
(60.6%)∗∗∗
0.09 ± 0.02
(54.6%)∗∗
0.10 ± 0.02
—
0.02 ± 0.001
(51.2%)
0.08 ± 0.02
(45.3%)
0.13 ± 0.03
(17.7%)
0.10 ± 0.03
(4.9%)
SDE 100 0.10 ± 0.02
(35.6%)
0.08 ± 0.02
(69.5%)∗∗∗
0.05 ± 0.02
(74.5%)∗∗∗
0.03 ± 0.01
(45.6%)
0.01 ± 0.01
(75.3%)
0.11 ± 0.03
(27.9%)
0.11 ± 0.03
(29.8%)
0.07 ± 0.03
(29.9%)
SDE 200 0.03 ± 0.01
(79.7%)∗∗∗
0.04 ± 0.01
(83.1%)∗∗∗
0.04 ± 0.01
(77.0%)∗∗∗
0.07 ± 0.02
—
0.021 ± 0.01
(44.2%)
0.06 ± 0.02
(59.5%)∗
0.08 ± 0.02
(47.5%)
0.065 ± 0.02
(37.3%)
SDE 400 0.02 ± 0.01
(82.4%)∗∗∗
0.06 ± 0.01
(76.9%)∗∗∗
0.058 ± 0.01
(67.8%)∗∗∗
0.04 ± 0.01
(20.9%)
0.020 ± 0.01
(47.7%)
0.05 ± 0.02
(69.9%)∗
0.05 ± 0.02
(70.9%)
0.03 ± 0.01
(69.8%)
Paw edemawasmeasuredwith a caliper; results were expressed as paw edema inmm3 (mean± SEM); treatments:P. umbellatum SDE (100, 200, and 400mg/kg),
vehicle (PBS, pH 7.0 + Tween 80 0.3%), or indomethacin (10mg/kg) one hour before intraplantar carrageenan 2.5% injection, 𝑛 = 8 animals/group. ANOVA,
Newman-Keuls Multiple Comparison Test; ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001 in comparison to negative control group (vehicle).
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Figure 2: Anti-inflammatory effect of P. umbellatum SDE versus
time after inflammatory stimulus on carrageenan-induced paw
edema. Paw edema was measured with a caliper; results were
expressed as paw edema in mm3 (mean ± SEM); treatments: P.
umbellatum SDE (100, 200, and 400mg/kg), vehicle (PBS, pH 7.0 +
Tween 80 0.3%), or indomethacin (10mg/kg) one hour before
intraplantar carrageenan 2.5% injection. 𝑛 = 8 animals/group.
ANOVA, Newman-Keuls Multiple Comparison Test; ∗𝑃 < 0.05,
∗∗
𝑃 < 0.01, and ∗∗∗𝑃 < 0.001 in comparison to negative control
group (vehicle).
hours, coinciding with a decrease in edema, but an increase
in leukocytes migration, which amplify the inflammatory
response and promote a second edema peak within 72 h [23].
P. umbellatum SDE treatment significantly inhibited the
first phase of inflammation, in an independent-dose way, as
well as indomethacin 10mg/kg (Figure 2 and Table 3). SDE
was able to inhibit inflammation up to 4.5 hours, period
coincidentwith prostaglandin release, which could suggest an
action on prostaglandins production (Figure 2 and Table 3).
In the second phase, all SDE doses inhibited inflammation
at 48 hours while 400mg/kg dose also inhibited the second
inflammatory peak (72 h). This result suggests an effect on
neutrophil mobilization, quite similar to the corticosteroids
effects that efficiently inhibit the cellular phase of inflamma-
tion.
Previous studies performed with P. umbellatum ethanolic
extract demonstrated its anti-inflammatory activity, with
inhibition of the first phase of inflammation [5]. Another
study showed the anti-inflammatory activity of a 𝛽-sitosterol
rich fraction obtained from Sideris foetens, which was able
to inhibit paw edema increase from 3 to 7 hours after
inflammatory stimulus [36]. According to these authors, 𝛽-
sitosterols could be responsible for the inhibition of arachido-
nate metabolites generation and neutrophil migration phase.
This way, the anti-inflammatory effect herein described for
P. umbellatum SDE, at higher dose, could be partly explained
by the presence of sitosterols derivatives. Additionally, Nu´n˜ez
et al. [37] observed that P. umbellatum ethanolic crude extract
and 4-NC inhibited the PLA
2
enzymatic activity, which could
also explain the SDE inhibitory effect on the first phase of
inflammation (arachidonate metabolites generation).
Cytotoxic agents may inhibit the cellular phase of inflam-
mation as demonstrated by Vendramini-Costa et al. [38].
These authors showed that doxorubicin inhibited the second
phase of carrageenan-induced inflammation (after 24 hours
of inflammation induction), which can be due to its cytotoxic
effect on leukocytes, thus inhibiting their migration. As P.
umbellatum SDE inhibited the second phase of carrageenan-
induced inflammation (Figure 2) and tumor cell prolifera-
tion (Table 1 and Figure 1), we performed the carrageenan-
induced peritonitis model to evaluate SDE activity on leuko-
cyte migration.
Carrageenan when inoculated in the peritoneum exerts
a chemotactic effect on inflammatory cells mediated by a
synergistic action between prostaglandins, leukotrienes, and
other chemotactic agents, producing a sustained increase
in postcapillary venule permeability, which leads to cellular
infiltration [39].
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Figure 3: Effect of P. umbellatum SDE on carrageenan-induced
peritonitis, expressed as leukocyte count (cells/mL). Results were
expressed as mean ± SEM (𝑛 = 8 animals/group); treatment: P.
umbellatum SDE (200mg/kg), vehicle (PBS, pH 7.0 + Tween 80
0.3%), or dexamethasone (5mg/kg), one hour before intraperitoneal
carrageenan (500 𝜇g/250 𝜇L) injection. Peritoneal fluid was col-
lected 4 hours after carrageenan stimulus. ANOVA, Newman-Keuls
Multiple Comparison Test, ∗∗𝑃 < 0.01 in comparison to negative
control group (vehicle).
In the carrageenan-induced peritonitis model, leuko-
cytes migration in the negative control group was 14160 ±
1705 cells/mL and cell migration was inhibited both by
dexamethasone (60.5%, 5mg/kg) and by P. umbellatum SDE
(52.0%, 200mg/kg), 𝑃 < 0.01 (Figure 3). These results
corroborated that SDE could inhibit PLA
2
activity in a similar
way as dexamethasone. PLA
2
is involved in arachidonic
acid release from membrane phospholipids, which can be
metabolized by cyclooxygenase (COX), lipoxygenase (LOX),
and cytochrome P450 enzymes [34].
Based on the results presented here, we conclude that
P. umbellatum SDE has promising antitumor and anti-
inflammatory activities, without side effects even in high
doses. In line with P. umbellatum SDE profile on paw
edema and peritonitis model and previous reports on PLA
2
inhibition, we hypothesize that SDE interferes on arachido-
nate metabolites generation, by inhibiting PLA
2
or COX-2
activities. Further studies will be performed to clarify the bio-
chemical pathways involved in these activities. These results
highlight the importance of Piper umbellatum as a potential
source of compounds against cancer and inflammation.
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